Gilead Sciences Inc Stock Price, News & Analysis

Kite, a Gilead (NASDAQ: GILD) subsidiary, has announced the acquisition of Interius BioTherapeutics for $350 million in cash. The acquisition focuses on Interius's innovative in vivo CAR therapeutics platform, which enables CAR T-cell generation directly within patients through a single intravenous infusion.

The platform eliminates the need for traditional cell harvesting, engineering, reinfusion, and preconditioning chemotherapy. The transaction is expected to impact Gilead's 2025 EPS by $0.23-$0.25. Interius's operations will be integrated into Kite's research team, establishing a center of excellence in Philadelphia for developing next-generation in vivo therapies.

Gilead Sciences (Nasdaq: GILD) has announced its participation in four major investor conferences in September 2025. The company's executives will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Annual Global Healthcare Conference (Sept 9), and Baird Global Healthcare Conference (Sept 10).

All presentations will be accessible via live webcasts on Gilead's investor relations website, with replays available for at least 30 days after each event.

Gilead Sciences (NASDAQ:GILD) reported strong Q2 2025 financial results with total revenue increasing 2% to $7.1 billion. Product sales excluding Veklury grew 4% to $6.9 billion, driven by HIV portfolio growth, particularly Biktarvy sales increasing 9% to $3.5 billion.

The company achieved diluted EPS of $1.56 and non-GAAP EPS of $2.01. Key highlights include FDA approval for Yeztugo as the first twice-yearly HIV prevention option and increased 2025 guidance. HIV product sales grew 7% to $5.1 billion, while Trodelvy sales increased 14% to $364 million.

Gilead raised its full-year 2025 guidance, now expecting product sales between $28.3-$28.7 billion and non-GAAP diluted EPS of $7.95-$8.25.

Gilead Sciences (Nasdaq: GILD) received positive CHMP opinions for lenacapavir, its injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP) in the European Union. If approved, lenacapavir, to be marketed as Yeytuo®, would become the first and only twice-yearly HIV PrEP option in the EU.

The recommendation is supported by data from the Phase 3 PURPOSE trials, where lenacapavir demonstrated remarkable efficacy: zero HIV infections among 2,134 participants in PURPOSE 1, and only two HIV infections among 2,179 participants in PURPOSE 2, showing superiority over daily oral Truvada.

The CHMP also adopted a positive EU-M4all opinion, which will help facilitate availability in low and lower-middle-income countries. The final European Commission decision is expected later this year, with an additional year of market exclusivity granted for the new indication.

Gilead Sciences (NASDAQ:GILD) has scheduled the release of its Q2 2025 financial results for Thursday, August 7, 2025, after market close. The company's management will host a webcast at 4:30 PM Eastern Time to discuss the quarterly results and provide a business update.

The live webcast will be accessible through the Investors section of Gilead's website and will remain archived for one year. Gilead Sciences is a biopharmaceutical company focused on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer, with operations in over 35 countries.

Gilead Sciences (NASDAQ:GILD) presented new Phase 3 PURPOSE trial data for Yeztugo® (lenacapavir), the first and only FDA-approved twice-yearly HIV prevention injection. The data demonstrated that Yeztugo was effective and well-tolerated across diverse populations, including pregnant women, lactating mothers, adolescents, and young people.

Key findings showed zero HIV infections among 184 pregnant/lactating participants in the Yeztugo group, and strong efficacy in people aged 16-25 years. More than 75% of study participants preferred twice-yearly injectable PrEP over daily oral medication, with over 50% expressing strong preference.

Gilead has submitted regulatory applications in multiple countries and announced a strategic partnership with The Global Fund to supply lenacapavir doses at no profit, aiming to reach up to 2 million people over three years in supported countries.

Gilead Sciences (Nasdaq: GILD) has finalized a strategic partnership with the Global Fund to provide its twice-yearly injectable HIV prevention drug lenacapavir at no profit. The agreement aims to reach up to 2 million people over three years in primarily low- and lower-middle-income countries.

The partnership builds on Gilead's October 2024 initiative granting non-exclusive, royalty-free voluntary licenses for generic lenacapavir manufacturing in 120 high-incidence, resource-limited countries. The company will supply the medicine at no profit until licensed generic versions can fully meet demand. The Global Fund will prioritize early-access countries based on HIV epidemiology, national prevention strategies, and available resources.

Gilead Sciences (NASDAQ: GILD) and Kymera Therapeutics (NASDAQ: KYMR) have entered into an exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders for cancer treatment. The collaboration focuses on developing a new type of drug designed to remove CDK2, a key protein in tumor growth, rather than just inhibiting it.

Under the agreement, Kymera could receive up to $750 million in total payments, including $85 million in upfront and potential option exercise payments, plus tiered royalties ranging from high single-digit to mid-teens on net sales. Kymera will lead research activities, while Gilead will gain global rights upon exercising its option. The deal is expected to impact Gilead's 2025 EPS by approximately $0.02-$0.03.

Gilead Sciences (GILD) has achieved a major breakthrough with FDA approval of Yeztugo (lenacapavir), the first and only twice-yearly injectable HIV prevention option. The drug demonstrated exceptional efficacy in Phase 3 trials, with ≥99.9% of participants remaining HIV negative. PURPOSE 1 trial showed zero HIV infections among 2,134 participants, while PURPOSE 2 had only two infections among 2,179 participants. The approval addresses significant gaps in PrEP adoption, as CDC data shows only 36% of eligible individuals currently use PrEP. Gilead is implementing broad access strategies, including assistance programs for both insured and uninsured patients. The drug has received Priority Review and Breakthrough Therapy Designation, with regulatory filings underway globally. This innovation represents a significant advancement in HIV prevention, potentially transforming treatment adherence and reducing stigma-related barriers.